VolitionRx Limited (VNRX)
| Market Cap | 8.33M -89.1% |
| Revenue (ttm) | 2.47M +88.5% |
| Net Income | -24.60M |
| EPS | -4.20 |
| Shares Out | 8.33M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 176,835 |
| Open | 1.100 |
| Previous Close | 1.080 |
| Day's Range | 0.990 - 1.100 |
| 52-Week Range | 0.990 - 16.000 |
| Beta | 1.12 |
| Analysts | Buy |
| Price Target | 16.97 (+1,597.0%) |
| Earnings Date | Aug 13, 2026 |
About VNRX
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient’s c... [Read more]
Financial Performance
In 2025, VolitionRx's revenue was $1.73 million, an increase of 40.04% compared to the previous year's $1.23 million. Losses were -$23.36 million, -13.39% less than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for VNRX stock is "Buy." The 12-month stock price target is $16.97, which is an increase of 1,597.00% from the latest price.
News
VolitionRx registers to sell 3.31M shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 3.31M shares of common stock. The company is not selling any…
VolitionRx Registration statement: Registration filing
VolitionRx filed a registration statement on July 10, 2026, providing details about a securities offering with the SEC.
VolitionRx announces data on prognostic value of Nu.Q Cancer Assay
VolitionRx (VNRX) announces the release of a new clinical study demonstrating the significant prognostic value of its Nu.Q Cancer Assay in newly diagnosed lung cancer patients, which could help clinic...
VolitionRx Announces Data Showing the Prognostic Value of its Nu.Q® Cancer Test
HENDERSON, Nev., July 7, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the release of a new clinical study demonstra...
VolitionRx resumed with a Buy at Maxim
Maxim resumed coverage of VolitionRx (VNRX) with a Buy rating and $4 price target The company is on track for significant progress across its diagnostic portfolio, including its core franchises:…
VolitionRx announces collaboration with Sysmex
VolitionRx (VNRX) announces a collaboration with Sysmex, a leader in global in vitro diagnostics, to optimize Volition’s Nu.Q NETs H3.1 assay on the Sysmex platform.
VolitionRx Announces Collaboration with Sysmex
HENDERSON, Nev., June 17, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces a collaboration with Sysmex (TYO: 6869), a leader ...
VolitionRx Announces Pricing of $4.6 Million Public Offering
$4.6 million upfront with up to an additional $2.3 million of potential aggregate gross proceeds upon the full exercise of warrants HENDERSON, Nev., June 7, 2026 /PRNewswire/ -- VolitionRx Limited (NY...
VolitionRx files patent covering Nu.Q technology for Ebola triage
VolitionRx (VNRX) announces that it has expanded its intellectual property portfolio by filing a strategic patent application covering the use of its proprietary Nu.Q technology in triaging and monito...
VolitionRx Files New Patent Protecting its Nu.Q® NETs Test for Ebola Triage and Treatment Monitoring
Seeks Strategic Partners to Deploy Nu.Q® Platform in Outbreak Zones HENDERSON, Nev., June 3, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics co...
VolitionRx Proxy statement: Proxy filing
VolitionRx filed a proxy statement on June 2, 2026, providing details for shareholder voting and corporate governance matters.
VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets
Update Highlights 300% Q1 Revenue Growth, Advance Toward $5 Million Veterinary Milestone, and Active Licensing Discussions with More Than a Dozen Global Diagnostic Leaders HENDERSON, Nev., May 27, 202...
VolitionRx Earnings Call Transcript: Q1 2026
Revenue surged 300% year-over-year to $1 million, driven by deferred revenue from the Nu.Q Vet agreement, while operating expenses rose due to R&D and severance costs. Major product milestones included validation of the feline cancer assay and advances in liquid biopsy technology.
VolitionRx Earnings release: Q1 2026
VolitionRx released its Q1 2026 earnings on May 15, 2026, summarizing the period's financial results.
VolitionRx Quarterly report: Q1 2026
VolitionRx has published its Q1 2026 quarterly earnings report on May 15, 2026.
VolitionRx Slides: Investor presentation
VolitionRx has posted slides in relation to its latest quarterly earnings report, which was published on May 15, 2026.
VolitionRx reports Q1 revenue $1M, consensus $409,920
Cameron Reynolds, President and Group Chief Executive Officer, said: “We have made strong progress across all of our product pillars during the first quarter and indeed subsequent to quarter end.
VolitionRx Limited Announces First Quarter 2026 Financial Results and Business Update
Conference call to discuss financial and operational results scheduled for Friday, May 15 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev.
VolitionRx Proxy statement: Proxy filing
VolitionRx filed a proxy statement on May 13, 2026, providing details for shareholder voting and corporate governance matters.
VolitionRx Limited Schedules First Quarter 2026 Earnings Conference Call and Business Update
Conference call to take place on Friday, May 15 at 8:30 a.m. U.S Eastern Time HENDERSON, Nev.
VolitionRx submits manuscript for Nu.Q Vet cancer test in cats
VolitionRx (VNRX) announced submission for peer review a clinical manuscript reporting the accuracy of its Nu.Q Vet Feline prototype assay in detecting lymphoma in cats, the most common cancer in…
VolitionRx Announces Submission of Manuscript for Nu.Q® Vet Cancer Test in Cats
The publication of this study in a peer reviewed journal is expected subsequently to unlock a $5 million contractual milestone payment HENDERSON, Nev., May 6, 2026 /PRNewswire/ -- VolitionRx Limited (...
VolitionRx announces milestone in nucleosomes detection
VolitionRx (VNRX) announces a major technical milestone with the successful detection of nucleosomes in capillary blood from critically ill sepsis patients using its lateral flow prototype. This finge...
Volition Announces Breakthrough Finger-Prick Detection of Nucleosomes; Expanding Global Market Potential for Sepsis Testing
HENDERSON, Nev., April 29, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces a major technical milestone with the succes...
VolitionRx’s compliance plan accepted by NYSE American
VolitionRx (VNRX) announced that on April 22, the NYSE American accepted the company’s plan of compliance for continued listing on the exchange. On February 6, the company received a notice…